Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00137930 | Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis | PHASE2 | COMPLETED | 250 | — | — | Aug 1, 2005 | Nov 1, 2005 | Sep 21, 2016 | 5 | Finland |
| Name | Type | Description |
|---|---|---|
| Live attenuated rotavirus vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Subjects with parents/guardians who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study. * Males or females between, and including, 6 and 12 weeks (42 - 90 days) of age at the time of the first vaccination. * Writ...